106.00 +1.02 (0.97%)
Pre-Market: 7:45AM EST
Previous Close | 110.21 |
Open | 109.86 |
Bid | 106.35 x 900 |
Ask | 106.53 x 800 |
Day's Range | 104.24 - 109.86 |
52 Week Range | 28.00 - 131.00 |
Volume | 1,093,391 |
Avg. Volume | 2,908,144 |
Market Cap | 25.278B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | Nov 10, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 119.09 |
President Joe Biden confirmed late Tuesday that drug giant Merck will step in to help its rival, supply-constrained Johnson and Johnson, manufacture its much-needed coronavirus vaccine.
The U.S. COVID-19 vaccine program is expected to get a welcome jolt on Tuesday in the news that one of the biggest vaccine makers in the world will help make Johnson & Johnson's one-dose jab, potentially doubling the supply from what J&J could achieve on its own.
France has used only a quarter of its AstraZeneca COVID-19 vaccine doses, a health ministry official indicated on Tuesday, saying its utilisation rate stood at 24% as of Feb. 28, well below a target set at 80-85%. This compares with 82% for vaccines made by Pfizer/BioNTech and 37% for those made by Moderna. "It is true that we are facing issues with AstraZeneca vaccines," the official said without elaborating.